Heron Therapeutics, Inc. (LON:0J4V)

Market Cap	56.42M -72.8%
Revenue (ttm)	114.13M +1.5%
Net Income	-23.43M
EPS	-0.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,815
Open	0.4163
Previous Close	0.4001
Day's Range	0.4069 - 0.4163
52-Week Range	0.3993 - 2.2950
Beta	1.57
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Heron Therapeutics

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 128
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J4V

Financial Performance

In 2025, Heron Therapeutics's revenue was $154.90 million, an increase of 7.36% compared to the previous year's $144.29 million. Losses were -$20.20 million, 48.7% more than in 2024.

Financial numbers in USD